Healthcare-Associated Pneumonia
10
1
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
10.0%
1 terminated out of 10 trials
85.7%
-0.8% vs benchmark
20%
2 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study
Application of Ventilator-Associated Events (VAE) in Ventilator-Associated Pneumonia (VAP) Notified in Brazil
Trial of Antimicrobial Restraint in Presumed Pneumonia
Hospital-acquired Pneumonia Prevention: Intervention, Evaluation & Research
Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
Comparison of Solid Organ Transplant
Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria
Impact of a Multidimensional Intervention in Elderly Patients With Pneumonia
Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia
Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients